ACHIEVEMENT OF STRINGENT EFFICACY ENDPOINTS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE TREATED WITH UPADACITINIB

Silvio Danese  ¹     Brian G. Feagan  ^{2, 3, 3}     Peter L Lakatos  ⁴     James O. Lindsay  ⁵     Tadakazu Hisamatsu  ⁶     Britta Siegmund  ^{7, 8}     Elena Dubcenco  ⁹     Ana Paula Machado De Lacerda  ⁹     Andrew Garrison  ⁹     Chirag Doshi  ⁹     James D. Lewis  ^10    
1 IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy
² Alimentiv, London, Canada
³ Western University, London, Canada
⁴ McGill University Health Centre, Montreal, Canada
⁵ Blizard Institute, Barts Health NHS Trust, London, United Kingdom
⁶ Kyorin University School of Medicine, Mitaka, Japan
⁷ Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
⁸ Campus Benjamin Franklin, Berlin, Germany
⁹ AbbVie Inc., North Chicago, United States
¹⁰ University of Pennsylvania, Philadelphia, United States

Topic
IBD

Session
PP 05 IBD (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)